TY - JOUR
T1 - The burden of myeloma
T2 - novel approaches to disease assessment
AU - Ho, Matthew
AU - Kourelis, Taxiarchis
N1 - Publisher Copyright:
© 2022 by The American Society of Hematology.
PY - 2022/12/9
Y1 - 2022/12/9
N2 - Novel therapies in multiple myeloma (MM) have increased the rates of conventional complete remission (CR) in patients. However, patients in CR can have highly heterogeneous outcomes. Novel and more sensitive methods of assessing residual disease burden after therapy will help prognosticate this group better and, ideally, allow individualized therapy adjustments based on response depth in the future. Here, we review novel bone marrow, peripheral blood, and imaging methods for assessing myeloma burden and discuss the opportunities and limitations of incorporating these in everyday clinical practice.
AB - Novel therapies in multiple myeloma (MM) have increased the rates of conventional complete remission (CR) in patients. However, patients in CR can have highly heterogeneous outcomes. Novel and more sensitive methods of assessing residual disease burden after therapy will help prognosticate this group better and, ideally, allow individualized therapy adjustments based on response depth in the future. Here, we review novel bone marrow, peripheral blood, and imaging methods for assessing myeloma burden and discuss the opportunities and limitations of incorporating these in everyday clinical practice.
UR - http://www.scopus.com/inward/record.url?scp=85143917260&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85143917260&partnerID=8YFLogxK
U2 - 10.1182/hematology.2022000348
DO - 10.1182/hematology.2022000348
M3 - Article
C2 - 36485143
AN - SCOPUS:85143917260
SN - 1520-4391
VL - 2022
SP - 356
EP - 362
JO - Hematology (United States)
JF - Hematology (United States)
IS - 1
ER -